Primary gout
Conditions
Interventions
Normal group (Standard urate-lowering therapy with febuxostat 20 to 40mg):NA
Overweight group (Standard urate-lowering therapy with febuxostat 20 to 40mg):NA
Obesity group (Standard urate-lowering therapy with febuxostat 20 to 40mg):NA
Sponsors
Affiliated Hospital of Qingdao University
Eligibility
Sex/Gender
Male
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Age range from 18 to 70 years old, male; 2.Meets the diagnostic criteria for primary gout, with serum uric acid = 7.0 mg/dL (416 µ mol/L); 3.eGFR = 30ml/min/1.73m2 and blood creatinine<177umol/L (normal renal function or compensatory period); 4. Voluntarily participate and sign an informed consent form.
Exclusion criteria
Exclusion criteria: The following criteria need to be excluded if any one of them is met: 1.Patients with severe gout stones or gout in chronic arthritis without significant remission. 2.Patients with active liver disease or cirrhosis, or liver dysfunction, with serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) exceeding the upper limit of the normal range by 2.5 times; 3.Bile duct diseases: patients with biliary malformations, gallstones, acute and chronic cholecystitis, and cholangitis; 4.Digestive tract diseases: patients with constipation, obstruction, and active gastrointestinal ulcers; 5.eGFR < 30ml/min/1.73m2 or blood creatinine (Cr) = 177umol/L; 6.Severe heart disease patients, such as decompensated heart failure (NYHA stage III and IV); Unstable angina pectoris; Have a history of myocardial infarction within the past 12 months, etc; 7.Patients with xanthineuria; 8.Rheumatoid arthritis and joint diseases caused by other reasons that require treatment; 9.Currently using drugs such as azathioprine, 6-mercaptopurine, cyclosporine, cyclophosphamide, thiazide, sulfamethoxazole, trimethoprim, theophylline, thiazide diuretics, aspirin (over 325mg/day) or other salicylic acid substances, losartan, intravenous colchicine for treatment; 10.Patients with secondary hyperuricemia caused by hematological diseases, kidney diseases, or tumor radiotherapy and chemotherapy; 11.Alcoholics or drug addicts; 12.Individuals who have participated in other clinical trials within the first three months of this trial screening; 13.Malignant tumors and active tuberculosis; 14.Concurrent with other diseases, and researchers believe that it affects efficacy evaluation or poor compliance; 15.Individuals taking glucocorticoid drugs; 16. White blood cell count<4.0 × 109/L, or platelets<100 × 109/L, or hemoglobin<90g/L;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum uric acid;BMI; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood pressure;Glutamic-pyruvic transaminase;Glutamic oxaloacetic transaminase;Fasting blood glucose;Triglyceride;Total cholesterol;High density lipoprotein;Low density lipoprotein;Creatinine;Glomerular filtration rate;CRP;CA72-4;24-hour urine microalbumin/creatinine;24-hour urine output;24-hour urine uric acid;24-hour urine creatinine;Urine PH;The frequency of acute gout; | — |
Countries
China
Contacts
Public ContactChanggui Li
Affiliated Hospital of Qingdao University
Outcome results
None listed